ADXN Addex Therapeutics Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1574232 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | 2025Q2*2025-06-30 | 2025-03-31*2025-03-31 | 2024Q2*2024-06-30 | 2024Q1*2024-03-31 | 2023Q2*2023-06-30 | 2023Q1*2023-03-31 | 2022Q2*2022-06-30 | 2022Q1*2022-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | 115,277 | — | 630,877 | — | 183,354 | — |
| R&D expense | 234,454 | — | 339,317 | — | 1.88M | — | 5.75M | — |
| SG&A expense | 534,819 | — | 675,276 | — | 1.30M | — | 1.53M | — |
| Operating income | -732,898 | — | -899,316 | — | -2.55M | — | -7.09M | — |
| Interest expense | 334 | — | 437 | — | 93 | — | 7,574 | — |
| Pretax income | -1.96M | — | -1.46M | — | -2.68M | — | -7.22M | — |
| Income tax | — | — | — | — | 0 | — | 0 | — |
| Net income | -1.84M | -1.47M | 12.88M | -3.09M | -2.68M | -2.41M | -7.22M | -5.82M |
| EPS (basic) | -0.02 | — | 0.13 | — | -0.04 | — | -0.19 | — |
| EPS (diluted) | -0.02 | — | 0.13 | — | -0.04 | — | -0.19 | — |
| Weighted avg. shares (diluted) | 100.52M | — | 98.31M | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | 2.30M | — | 3.79M | — | 7.17M | — | 8.81M | — |
| Receivables | 38,439 | — | — | — | 255,656 | — | 331,770 | — |
| Current assets | 2.66M | — | — | — | 8.69M | — | 10.95M | — |
| PP&E, netmay include right-of-use assets (IFRS) | 919 | — | — | — | 33,154 | — | 54,431 | — |
| Total assets | 8.51M | — | — | — | 9.00M | — | 11.38M | — |
| Current liabilities | 1.15M | — | — | — | 2.71M | — | 4.30M | — |
| Total liabilities | 1.29M | — | — | — | 2.87M | — | 4.52M | — |
| Shareholders' equity | 7.21M | 8.30M | 12.65M | -1.37M | 6.13M | 4.07M | 6.86M | 12.96M |
| Shares outstanding | 141.19M | — | 128.25M | — | 92.35M | — | 37.88M | — |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | — | — | — | — |
| Capital expenditure | 0 | — | 0 | — | — | — | — | — |
| Stock-based compensation | 1,851 | — | 4,701 | — | 416,947 | — | 550,221 | — |
Free plan shows the latest 8 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.